Modality
mAb
MOA
PRMT5i
Target
TYK2
Pathway
Proteasome
AML
Development Pipeline
Preclinical
Nov 2019
→ Apr 2031
PreclinicalCurrent
NCT06082497
1,183 pts·AML
2019-11→2031-04·Terminated
1,183 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-03-202w agoEnrollment Complete· AML
2031-04-145.0y awayInterim· AML
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
Preclinical
Termina…
Catalysts
Enrollment Complete
2026-03-20 · 2w ago
AML
Interim
2031-04-14 · 5.0y away
AML
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06082497 | Preclinical | AML | Terminated | 1183 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| VRT-1891 | Vertex Pharma | Phase 1 | KRASG12C |